Почетна › Akutna mijeloidna leukemija › Minesota
Kliničke studije za Akutna mijeloidna leukemija u državi Minesota
28 studija za Akutna mijeloidna leukemija traži učesnike na lokacijama u državi Minesota.
Gradovi u državi Minesota
- Minneapolis19 студија
- Rochester13 студија
- Saint Paul7 студија
- Bloomington6 студија
- Duluth6 студија
- Brooklyn Park6 студија
Zvanični tekst studije (na engleskom)
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
- Mercy Hospital, Coon Rapids
- Essentia Health - Deer River Clinic, Deer River
- Essentia Health Cancer Center, Duluth
- и још 9
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT06317649Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
- University of Minnesota, Minneapolis
- HealthPartners Cancer Center at Regions Hospital (MN), Saint Paul
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT07007312Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
- Mercy Hospital, Coon Rapids
- Essentia Health - Deer River Clinic, Deer River
- Essentia Health Cancer Center, Duluth
- и још 10
Тражи се учесникФаза 2
Узраст од 18 до 59 · Оба пола · Ажурирано 9. 11. 2026. · NCT05554406Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
- Sanford Joe Lueken Cancer Center, Bemidji
Тражи се учесникФаза 2
Узраст 60 и старији · Оба пола · Ажурирано 6. 11. 2026. · NCT07437950Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Riverwood Healthcare Center, Aitkin
- Mayo Clinic Health System in Albert Lea, Albert Lea
- Essentia Health - Baxter Clinic, Baxter
- и још 49
Тражи се учесникОпсервациона студијаЗдраве особе су добродошле
Узраст од 40 до 75 · Оба пола · Ажурирано 4. 11. 2026. · NCT05334069MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- Sanford Joe Lueken Cancer Center, Bemidji
- Mercy Hospital, Coon Rapids
- Essentia Health - Deer River Clinic, Deer River
- и још 10
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 2. 11. 2026. · NCT05564390CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
- Mayo Clinic Hospital - Rochester, Rochester
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 28. 10. 2026. · NCT05143996Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- Mercy Hospital, Coon Rapids
- Essentia Health - Deer River Clinic, Deer River
- Essentia Health Cancer Center, Duluth
- и још 9
Тражи се учесникФаза 2
Узраст од 18 до 59 · Оба пола · Ажурирано 28. 10. 2026. · NCT05554393Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
- Mercy Hospital, Coon Rapids
- Essentia Health - Deer River Clinic, Deer River
- Essentia Health Cancer Center, Duluth
- и још 9
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 27. 10. 2026. · NCT06672146Immune Profile of Acute Myeloid Leukemia Patients Receiving Azacitidine Plus Venetoclax Induction Chemotherapy
- Mayo Clinic in Rochester, Rochester
Тражи се учесникОпсервациона студија
Узраст 18 и старији · Оба пола · Ажурирано 26. 10. 2026. · NCT06279572A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia
- University of Minnesota/Masonic Cancer Center, Minneapolis
Тражи се учесникФаза 1
До 21 година · Оба пола · Ажурирано 23. 10. 2026. · NCT07012044Phase I/II Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagnosed TP53-mutated Acute Myeloid Leukemia (AML)
- Masonic Cancer Center, Minneapolis
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 23. 10. 2026. · NCT07008638A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
- Children's Hospitals and Clinics of Minnesota - Minneapolis, Minneapolis
- University of Minnesota/Masonic Cancer Center, Minneapolis
- Mayo Clinic in Rochester, Rochester
Тражи се учесникФаза 3
6 Months – 21 Years · Оба пола · Ажурирано 17. 9. 2026. · NCT04293562Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
- Mayo Clinic, Rochester
Тражи се учесникФаза 1/2
Узраст 12 и старији · Оба пола · Ажурирано 3. 9. 2026. · NCT04588922Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
- US-Rochester MN-MAYOMN, Rochester
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 2. 9. 2026. · NCT06652438The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Children's Hospitals and Clinics of Minnesota - Minneapolis, Minneapolis
- University of Minnesota/Masonic Cancer Center, Minneapolis
- Mayo Clinic in Rochester, Rochester
Тражи се учесникФаза 1/2
До 22 година · Оба пола · Ажурирано 25. 8. 2026. · NCT04726241HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML
- Masonic Cancer Center, Minneapolis
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 14. 7. 2026. · NCT06594445Allo HSCT Using RIC and PTCy for Hematological Diseases
- Masonic Cancer Center at University of Minnesota, Minneapolis
Тражи се учесникФаза 2
До 75 година · Оба пола · Ажурирано 6. 7. 2026. · NCT05805605Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
- Masonic Cancer Center at University of Minnesota, Minneapolis
Тражи се учесникФаза 2
До 60 година · Оба пола · Ажурирано 25. 6. 2026. · NCT03314974A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
- Mayo Clinic in Rochester, Rochester
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 10. 6. 2026. · NCT03017820Adapt NK for High Risk Myeloid Diseases as Bridge to Allo HSCT
- Mark Juckett, MD, Minneapolis
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 19. 5. 2026. · NCT07591649MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases
- Masonic Cancer Center at University of Minnesota, Minneapolis
Тражи се учесникФаза 2
Узраст од 2 до 75 · Оба пола · Ажурирано 16. 4. 2026. · NCT07493538A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes
- Mayo Clinic Comprehensive Cancer Center, Rochester
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 13. 4. 2026. · NCT05732103Backtracking Leukemia-Typical Somatic Mutations in Cord Blood
- University of Minnesota/Masonic Cancer Center, Minneapolis
Тражи се учесникОпсервациона студија
До 25 година · Оба пола · Ажурирано 8. 4. 2026. · NCT05014165MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
- University of Minnesota Masonic Cancer Center, Minneapolis
Тражи се учесникФаза 2
До 60 година · Оба пола · Ажурирано 6. 4. 2026. · NCT05735717A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
- University of Minnesota, Minneapolis
- Mayo Clinic - Rochester, Rochester
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 13. 3. 2026. · NCT05735184A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)
- Mayo Clinic, Rochester
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 9. 2. 2026. · NCT06950034Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia
- Mayo Clinic, Rochester
Тражи се учесникЗдраве особе су добродошле
Узраст од 18 до 120 · Оба пола · Ажурирано 25. 7. 2025. · NCT05237258Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.